Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nifedipine + losartan is a fixed-dose combination of two antihypertensive agents used to treat high blood pressure. Nifedipine is a calcium channel blocker that inhibits the influx of calcium ions into vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced blood pressure. Losartan is an angiotensin II receptor blocker (ARB) that selectively blocks the binding of angiotensin II to the AT1 receptor, resulting in vasodilation, decreased aldosterone secretion, and further reduction in blood pressure. The combination provides additive or synergistic effects on lowering systolic and diastolic blood pressure compared with either agent alone, as well as enhanced organ protection such as reduced left ventricular hypertrophy and improved renal outcomes[1][2][4]. This combination may be particularly beneficial for patients who require more than one medication for effective hypertension control.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on nifedipine + losartan.